Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

导出原文传递

翻译打印收藏纠错

作者： Adam L,Boxer ^[1] ; Irfan,Qureshi ^[2] ; Michael,Ahlijanian ^[2] ; Michael,Grundman ^[3] ; Lawrence I,Golbe ^[4] ; Irene,Litvan ^[5] ; Lawrence S,Honig ^[6] ; Paul,Tuite ^[7] ; Nikolaus R,McFarland ^[8] ; Padraig,O'Suilleabhain ^[9] ; Tao,Xie ^[10] ; Giridhar S,Tirucherai ^[2] ; Clifford,Bechtold ^[2] ; Yvette,Bordelon ^[11] ; David S,Geldmacher ^[12] ; Murray,Grossman ^[13] ; Stuart,Isaacson ^[14] ; Theresa,Zesiewicz ^[15] ; Tina,Olsson ^[16] ; Kumar Kandadi,Muralidharan ^[16] ; Danielle L,Graham ^[16] ; John,O'Gorman ^[16] ; Samantha Budd,Haeberlein ^[16] ; Tien,Dam ^[17]

作者单位： University of California, San Francisco, CA, USA. ^[1] Bristol-Myers Squibb, Lawrenceville, NJ, USA. ^[2] Global R&D Partners, LLC, San Diego, CA, USA; University of California, San Diego, CA, USA. ^[3] Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. ^[4] University of California, San Diego, CA, USA. ^[5] Columbia University Irving Medical Center, New York, NY, USA. ^[6] University of Minnesota, Minneapolis, MN, USA. ^[7] University of Florida, Gainesville, FL, USA. ^[8] University of Texas Southwestern Medical Center, Dallas, TX, USA. ^[9] University of Chicago, Chicago, IL, USA. ^[10] University of California, Los Angeles, CA, USA. ^[11] University of Alabama at Birmingham, Birmingham, AL, USA. ^[12] University of Pennsylvania, Philadelphia, PA, USA. ^[13] Boca Raton Institute for Neurodegenerative Disorders, Boca Raton, FL, USA. ^[14] University of South Florida, Tampa, FL, USA. ^[15] Biogen, Cambridge, MA, USA. ^[16] Biogen, Cambridge, MA, USA. Electronic address: tien.dam@biogen.com. ^[17]